Comparative Pharmacology
Head-to-head clinical analysis: PHENURONE versus VIMPAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENURONE versus VIMPAT.
PHENURONE vs VIMPAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Selective enhancement of slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Adults: 200 mg oral or IV as a loading dose, followed by 100 mg twice daily (200 mg/day) starting the day after loading. May increase by 50 mg twice daily every week up to 200 mg twice daily (400 mg/day).
None Documented
None Documented
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal half-life: 13-16 hours (mean ~13 h at steady state); prolonged with renal impairment (CrCl <30 mL/min: ~22 h) and in patients with hepatic impairment (Child-Pugh B: ~17 h; Child-Pugh C: ~22 h).
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Renal: ~95% (40% as parent drug, 39% as O-desmethyl metabolite, and ~15% as other minor metabolites); minimal biliary/fecal elimination (less than 1%).
Category C
Category C
Anticonvulsant
Anticonvulsant